tirzepatide fda obesity approves Lilly's Zepbound (tirzepatide) for chronic weight management Tirzepatide Wins FDA Approval for

GLP-1 receptor agonists mimic the GLP-1 peptide that's made by your body naturally

Phase 2 trial data published in 2023 in the New England Journal of Medicine (Jastreboff et al., NEJM 2023) reported mean weight reductions of up to approximately 24% over 48 weeks in adults with obesity notably higher than results seen with currently approved agents

He works closely with patients to develop personalized treatment plans that integrate medical therapy, lifestyle guidance, and ongoing monitoring helping patients achieve lasting results with clarity and confidence

For many individuals, the most significant weight loss is seen after 6 to 12 months of consistent use